Meta AnalysisID 6666
舒肝解郁胶囊对癫痫精神症状的有效性：系统评价与Meta分析方案
CRD42021238804
This review researched the effectiveness and safety of Shugan jieyu capsule for the treatment of psychiatric symptoms in epilepsy.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6666
- Evidence Id
- 15224
- Core Evidence Id
- 15224
- Source Meta Analysis Id
- 6649
- Herb2 Meta Analysis Id
- HBMA006649
- Crd Id
- CRD42021238804
- Title
- Effectiveness of the Shugan Jieyu capsule against psychiatric symptoms in epilepsy: A protocol for systematic review and meta-analysis
- Review Question
- This review researched the effectiveness and safety of Shugan jieyu capsule for the treatment of psychiatric symptoms in epilepsy.
- Study Type Included
- We will include randomized controlled trials assessing the effectiveness and the safety of Shugan jieyu capsule on psychiatric symptoms in epilepsy.
- Condition Being Studied
- Epilepsy is a chronic pathological condition of the brain that causes recurrent seizures. It is known that patients with epilepsy, particularly in the case of treatment-resistant epilepsy which accounts for one third to half, have an increased risk of psychological disorder. Psychiatric symptoms of epilepsy include not only depression, but also fatigue, sleep disturbances, anxiety, and memory problems. The relationship between epilepsy and psychiatric symptoms is known to be bidirectional. Clinically, epilepsy can influence the onset of depression through exposure to chronic stress, and depression increases the risk of epilepsy by 2 to 7 times. In addition, some antiepileptic drugs (AED) can either worsen or alleviate depression, which is still controversial. Anxiety and insomnia are also common symptoms of epilepsy, affecting epilepsy onset. AEDs can regulate the sleep-wake cycle by decreasing rapid eye movement and slow-wave sleep. Nevertheless, it is difficult for patients to aggressively receive adequate treatment for psychiatric symptoms. This is because there is no effective psychiatric drug criteria for patients with epilepsy, and there is a risk of exacerbating seizures. Moreover, psychiatric drugs are also revealed to worsen the side effects of AEDs. For example, even though depression in epilepsy is mainly treated with SSRI, FDA warns patients with seizures.
- Participant
- Participants who were diagnosed with epilepsy by the International Federation of Epilepsy in 1981 and complain of each psychiatric symptom (e.g. depression, anxiety, insomnia) verified by standardized criteria and/or scores of validated relevant questionnaires (e.g. Patient Health Questionnaire 9-item Depression and Hamilton Depression Rating Scale for depression) were included.
- Animal
- Human Disease Modelled
- Intervention
- Shugan jieyu capsule, a herbal medicine is composed of Acanthopanax senticosus and Hypericum perforatum. It has been widely taken to treat depression, cognitive disorder, stroke, functional dyspepsia, etc., since 2008 when it was registered. Acanthopanax senticosus reported to improve depressive disorder, ischemic stroke, and fatigue in previous clinical trials. Hypericum perforatum showed its effectiveness for depression clinically, and it is also reported to enhance cognitive function in preclinical study in rodents. The studies will be included if Shugan jieyu capsule was used solely or used with conventional treatment as an experimental intervention. In the case of combined form with conventional treatment, Shugan Jieyu capsule should be the only positive intervention and be compared with the same conventional treatment as a control group.
- Comparator Control
- All types of control such as placebo, conventional treatment or no treatment will be included.
- Main Outcome
- We defined the scope of psychiatric symptoms as depression, anxiety, and insomnia. (1) Depression will be measured with a validated depression scale (e.g. Hamilton Depression Rating Scale, Chinese-Neurological Disorders Depression Inventory for Epilepsy, Patient Health Questionnaire 9-item Depression). (2) Anxiety will be measured with a validated anxiety scale (e.g. Hamilton Anxiety Rating Scale, State-Trait Anxiety Inventory). (3) Insomnia will be measured with a validated anxiety scale (e.g. Pittsburgh Sleep Quality index, Insomnia Severity Index). (4) To find out antidepressant with the lowest risk of seizure exacerbation, frequency of monthly epileptic seizures will be measured. Measures of effect Mean differences
- Outcome Measure
- Additional Outcome
- (1) Adverse effects: measured by any relevant incidence and duration of any side effects. (2) Quality of life measured by a validated scale Measures of effect Relative risks, odds ratios
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Depression; Epilepsy; Humans; Mental Disorders
- Contact
- Sejin Kim [email protected]
- Organisational Affiliation
- College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea Department of Neuropsychiatry, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- South Korea
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-02-22
- Registration Date
- 2021-03-24
- Anticipated Start Date
- 2022-04-01
- Anticipated Completion Date
- 2022-08-31
- Title Cn
- 舒肝解郁胶囊对癫痫精神症状的有效性：系统评价与Meta分析方案
- Title En
- Effectiveness of the Shugan Jieyu capsule against psychiatric symptoms in epilepsy: A protocol for systematic review and meta-analysis
- Bilingual Status
- complete